The global nivolumab drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The generic name of Opdivo is Nivolumab, a targeted treatment medication. Nivolumab is currently approved for unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), advanced renal cell cancer, classical Hodgkin’s lymphoma (cHL), and recurrent or metastatic […]
